Nadim Ahamad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nadim Ahamad has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Rinti Banerjee
Department of Biosciences and Bioengineering, Indian Institute of Technology, Bombay, Powai, Mumbai, India
5 shared publications - Dhirendra S. Katti
Department of Biological Science and Bioengineering, Indian Institute of Technology Kanpur, Kanpur 208 016 (U.P), Kanpur, 208016, INDIA
2 shared publications Abhinanda Kar
Nanomedicine Laboratory, Biosciences and Bioengineering Department, Indian Institute of Technology Bombay, Mumbai, 400 076, India
1 shared publication- Ameya Prabhakar
Nanomedicine Laboratory
1 shared publication Atul Deshmukh
Oral & Maxillofacial Pathology & Immunohistochemistry Centre, Mumbai-400003, India
1 shared publication- Balaji Prakash
Department of Molecular Nutrition, CSIR-Central Food Technological Research Institute, Mysore, 570020, India
1 shared publication
Latest Publications
- 12 May 2022
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 8 (6) , 2232-2257
Nanotechnology Approaches for Rapid Detection and Theranostics of Antimicrobial Resistant Bacterial Infections
As declared by WHO, antimicrobial resistance (AMR) is a high priority issue with a pressing need to develop impactful technologies to curb it. The rampant and inappropriate use of antibiotics due to the lack of adequate and timely diagnosis is a leading cause behind AMR evolution. Unfortunately, populations with poor economic status and those residing in densely populated areas are the most affected ones, frequently leading to emergence of AMR pathogens. Classical approaches for AMR diagnostics like phenotypic methods, biochemical assays, and molecular techniques are cumbersome and resource-intensive and involve a long turnaround time to yield confirmatory results. In contrast, recent emergence of nanotechnology-assisted approaches helps to overcome challenges in classical approaches and offer simpler, more sensitive, faster, and more affordable solutions for AMR diagnostics. Nanomaterial platforms (metallic, quantum-dot, carbon-based, upconversion, etc.), nanoparticle-based rapid point-of-care platforms, nano-biosensors (optical, mechanical, electrochemical), microfluidic-assisted devices, and importantly, nanotheranostic devices for diagnostics with treatment of AMR infections are examples of rapidly growing nanotechnology approaches used for AMR management. This review comprehensively summarizes the past 10 years of research progress on nanotechnology approaches for AMR diagnostics and for estimating antimicrobial susceptibility against commonly used antibiotics. This review also highlights several bottlenecks in nanotechnology approaches that need to be addressed prior to considering their translation to clinics.
- 12 May 2022
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 8 (6) , 2232-2257
Nanotechnology Approaches for Rapid Detection and Theranostics of Antimicrobial Resistant Bacterial Infections
As declared by WHO, antimicrobial resistance (AMR) is a high priority issue with a pressing need to develop impactful technologies to curb it. The rampant and inappropriate use of antibiotics due to the lack of adequate and timely diagnosis is a leading cause behind AMR evolution. Unfortunately, populations with poor economic status and those residing in densely populated areas are the most affected ones, frequently leading to emergence of AMR pathogens. Classical approaches for AMR diagnostics like phenotypic methods, biochemical assays, and molecular techniques are cumbersome and resource-intensive and involve a long turnaround time to yield confirmatory results. In contrast, recent emergence of nanotechnology-assisted approaches helps to overcome challenges in classical approaches and offer simpler, more sensitive, faster, and more affordable solutions for AMR diagnostics. Nanomaterial platforms (metallic, quantum-dot, carbon-based, upconversion, etc.), nanoparticle-based rapid point-of-care platforms, nano-biosensors (optical, mechanical, electrochemical), microfluidic-assisted devices, and importantly, nanotheranostic devices for diagnostics with treatment of AMR infections are examples of rapidly growing nanotechnology approaches used for AMR management. This review comprehensively summarizes the past 10 years of research progress on nanotechnology approaches for AMR diagnostics and for estimating antimicrobial susceptibility against commonly used antibiotics. This review also highlights several bottlenecks in nanotechnology approaches that need to be addressed prior to considering their translation to clinics.
- Top Cited Papers
- 23 February 2022
- Published by Elsevier in Biomaterials
- Vol. 283, 121435
Wearable and implantable devices for drug delivery: Applications and challenges
- 23 February 2022
- Published by Elsevier in Biomaterials
- Vol. 283, 121435
Top Cited PapersWearable and implantable devices for drug delivery: Applications and challenges
- 1 August 2020
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 586, 119482
Enhanced absorption, and efficacy of oral self-assembled paclitaxel nanocochleates in multi-drug resistant colon cancer
- 1 August 2020
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 586, 119482
Enhanced absorption, and efficacy of oral self-assembled paclitaxel nanocochleates in multi-drug resistant colon cancer
- 18 May 2020
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 12 (24) , 12673-12697
Trigger-responsive engineered-nanocarriers and image-guided theranostics for rheumatoid arthritis
Rheumatoid Arthritis (RA), one of the leading causes of disability due to progressive autoimmune destruction of synovial joints, affects ∼1% of the global population. Standard therapy helps in reducing inflammation and delaying the progression of RA but is limited by non-responsiveness on long-term use and several side-effects. The conventional nanocarriers (CNCs), to some extent, minimize toxicity associated with free drug administration while improving the therapeutic efficacy. However, the uncontrolled release of the encapsulated drug even at off-targeted organs limits the application of CNCs. To overcome these challenges, trigger-responsive engineered nanocarriers (ENCs) have been recently explored for RA treatment. Unlike CNCs, ENCs enable precise control over on-demand drug release due to endogenous triggers in arthritic paws like pH, enzyme level, oxidative stress, or exogenously applied triggers like near-infrared light, magnetic field, ultrasonic waves, etc. As the trigger is selectively applied to the inflamed joint, it potentially reduces toxicity at off-target locations. Moreover, ENCs have been strategically coupled with imaging probe(s) for simultaneous monitoring of ENCs inside the body and facilitate an ‘image-guided-co-trigger’ for site-specific action in arthritic paws. In this review, the progress made in recently emerging ‘trigger-responsive’ and ‘image-guided theranostics’ ENCs for RA treatment has been explored with emphasis on the design strategies, mechanism, current status, challenges, and translational perspectives.
- 18 May 2020
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 12 (24) , 12673-12697
Trigger-responsive engineered-nanocarriers and image-guided theranostics for rheumatoid arthritis
Rheumatoid Arthritis (RA), one of the leading causes of disability due to progressive autoimmune destruction of synovial joints, affects ∼1% of the global population. Standard therapy helps in reducing inflammation and delaying the progression of RA but is limited by non-responsiveness on long-term use and several side-effects. The conventional nanocarriers (CNCs), to some extent, minimize toxicity associated with free drug administration while improving the therapeutic efficacy. However, the uncontrolled release of the encapsulated drug even at off-targeted organs limits the application of CNCs. To overcome these challenges, trigger-responsive engineered nanocarriers (ENCs) have been recently explored for RA treatment. Unlike CNCs, ENCs enable precise control over on-demand drug release due to endogenous triggers in arthritic paws like pH, enzyme level, oxidative stress, or exogenously applied triggers like near-infrared light, magnetic field, ultrasonic waves, etc. As the trigger is selectively applied to the inflamed joint, it potentially reduces toxicity at off-target locations. Moreover, ENCs have been strategically coupled with imaging probe(s) for simultaneous monitoring of ENCs inside the body and facilitate an ‘image-guided-co-trigger’ for site-specific action in arthritic paws. In this review, the progress made in recently emerging ‘trigger-responsive’ and ‘image-guided theranostics’ ENCs for RA treatment has been explored with emphasis on the design strategies, mechanism, current status, challenges, and translational perspectives.
- 1 May 2020
- Published by Elsevier in Acta Biomaterialia
- Vol. 108, 1-21
Advancements in prophylactic and therapeutic nanovaccines
- 1 May 2020
- Published by Elsevier in Acta Biomaterialia
- Vol. 108, 1-21
Advancements in prophylactic and therapeutic nanovaccines
- 1 January 2018
- Published by Elsevier in Tuberculosis
- Vol. 108, 47-55
Investigating the inhibitory potential of 2-Aminopurine metal complexes against serine/threonine protein kinases from Mycobacterium tuberculosis
- 1 January 2018
- Published by Elsevier in Tuberculosis
- Vol. 108, 47-55
Investigating the inhibitory potential of 2-Aminopurine metal complexes against serine/threonine protein kinases from Mycobacterium tuberculosis